GABA_A-receptor Subtypes: Clinical Efficacy and Selectivity of Benzodiazepine Site Ligands

References

• Liiddens H, Wisden W. Function and pharmacology of multiple GABAA receptor subunits. Trends Pharmacol Sci 1991; 12: 49–51
   PubMedGoogle Scholar
• Wisden W, Seeburg P H. GABAA receptor channels: from subunits to functional entities. Curr Opin Neurobiol 1992; 2: 263–9
   PubMedGoogle Scholar
• Macdonald R L, Olsen R W. GABAA receptor channels. Annu Rev Neurosci 1994; 17: 569–602
   PubMed Web of Science ®Google Scholar
• Liiddens H, Korpi E R. Biological function of GABAA/ benzodiazepine receptor heterogeneity. J Psychiat Res 1995; 29: 77–94
   PubMedGoogle Scholar
• Rabow L E, Russek S J, Farb D H. From ion currents to genomic analysis: recent advances in GABAA receptor research. Synapse 1995; 21: 189–274
   PubMed Web of Science ®Google Scholar
• Sieghart W. Structure and pharmacology of y-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47: 181–234
   PubMed Web of Science ®Google Scholar
• Stephenson F A. The GABAA receptors. Biochem J 1995; 310: 1–9
   PubMedGoogle Scholar
• Liiddens H, Korpi E R. GABAA receptors: pharmacology, behavioural roles, and motor disorders. Neuroscientlst 1996; 2: 15–23
   Google Scholar
• McKernan R, Whiting P J. Which GABAA-receptor subtypes really occur in the brain?. Trends Neurosci 1996; 19: 139–43
   PubMed Web of Science ®Google Scholar
• Ferry G. Cloned: the key to a tranquil brain. New Scientist 1987; 6: 26–7
   Google Scholar
• Gardner C R, Tully W R, Hedgecock C JR. The rapidly expanding range of neuronal benzodiazepine receptor ligands. Prog Neurobiol 1993; 40: 1–61
   PubMedGoogle Scholar
• Hunkeler W, Möhler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature 1981; 290: 514–6
   PubMed Web of Science ®Google Scholar
• Lamb R J, Griffiths R R. Effects of repeated Ro15–788 administration in benzodiazepine-dependent baboons. Eur J Pharmacol 1985; 110: 257–61
   PubMed Web of Science ®Google Scholar
• Buck K J, Heim H, Harris R A. Reversal of alcohol dependence and tolerance by a single administration of fluma-zenil. J Pharmacol Exp Ther 1991; 257: 984–9
   PubMedGoogle Scholar
• Harrisonread P E, Tyrer P, Lawson E, Lacks S, Fernades C, File S. Flumazenil-precipitated panic and dysforia in patients dependent on benzodiazepines - a possible aid to abstinence. J Psychopharmacol 1996; 10: 89–97
   PubMedGoogle Scholar
• Bonetti E P, Burkard W P, Gabl M, et al. Ro 15–4513, partial inverse agonism at the BZR and interaction with ethanol. Pharmacol Biochem Behav 1989; 31: 733–49
   Google Scholar
• Martin J R, Pieri L, Bonetti E P, et al. Ro 16–6028, a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 1988; 21: 360–2
   PubMedGoogle Scholar
• Giusti P, Ducic I, Puia G, et al. Imidazenil: a new partial allosteric modulator of GABA action at GABAA receptors. J Pharmacol Exp Ther 1993; 266: 1018–28
   PubMed Web of Science ®Google Scholar
• Ducic I, Puia G, Vicini S, Costa E. Triazolam is more efficacious than diazepam in a broad spectrum of recombinant GABAA receptors. Eur J Pharmacol - Mol Pharmacol Secf 1993; 244: 29–35
   PubMedGoogle Scholar
• Lader M. Rebound insomnia and newer hypnotics. Psycho-pharmacology 1992; 108: 248–55
   PubMed Web of Science ®Google Scholar
• Varhe A. Interactions of Triazolam with Inhibitors of CYP3A4 enzymes. Doctoral thesis, University of Helsinki, Helsinki 1996
   Google Scholar
• Stephens D N, Schneider H H, Kehr W, et al. Abecarnil, a metabolically stable, anxioselective β-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 1990; 253: 334–43
   PubMed Web of Science ®Google Scholar
• Ballenger J C, McDonald S, Noyes R, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112–19), in generalized anxiety disorder. Adv Biochem Psychopharmacol 1992; 47: 431–47
   PubMedGoogle Scholar
• Duka T, Shutt B, Krause W, et al. Human studies on abecarnil, a new β-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. Br J Clin Pharmacol 1993; 35: 386–94
   PubMedGoogle Scholar
• Salva R, Costa J. Clinical pharmacokinetics and pharmacodynamics of Zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29: 142–53
   PubMed Web of Science ®Google Scholar
• Crlswell H E, Simson P E, Duncan G E, et al. Molecular basis for regionally specific action of ethanol on γ-amino-butyric acidA receptors: generalization to other ligand-gated ion channels. J Pharmacol Exp Ther 1993; 267: 522–37
   PubMedGoogle Scholar
• Wilkinson C J. The acute effects of Zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry 1995; 56: 309–18
   PubMedGoogle Scholar
• DeClerc A, Bisserbe J C. Short-term safety profile of Zolpidem: objective measures of cognitive effects. Eur Psychiatry 1996; 11(Suppl 5)459S–64S
   Google Scholar
• Unden M, Roth Schecter B. Next day effects after nighttime with Zolpidem: a review. Eur Psychiatry 1996; 11(Suppl 1)21S–30S
   PubMedGoogle Scholar
• Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995; 18: 246–51
   PubMedGoogle Scholar
• Berlin I, Warot D, Hergueta T, Molinier P, Pagot C, Puech A. Comparison of the effects of Zolpidem and triazolam on memory functions, and psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993; 13: 100–6
   PubMedGoogle Scholar
• Wesenstein N J, Balkin T J, Belenky G L. Effects of daytime administration of Zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995; 48: 115–22
   PubMedGoogle Scholar
• Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharma-cology 1994; 116: 130–4
   PubMed Web of Science ®Google Scholar
• Mattila M J, Vanakoski J. Zolpidem, diazepam and zopiclone similarly impair human performance and memory. Br J Clin Pharmacol 1996; 42: 664P
   Google Scholar
• Lister R G. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985; 9: 87–94
   PubMed Web of Science ®Google Scholar
• Griffiths R R, Sannerud C, Ator N A, Brady J V. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance, and withdrawal. J Pharmacol Exp Ther 1992; 260: 1199–208
   PubMedGoogle Scholar
• Evans S, Funderburk F, Griffiths R R. Zolpidem and triazolam in humans: behavioral and subjective effects of abuse liability. J Pharmacol Exp Ther 1990; 255: 1246–55
   PubMed Web of Science ®Google Scholar
• Bruun T G. Abuse potential during use and withdrawal psychosis after treatment with the hypnotic Zolpidem (Stilnoct) (in Danish). Ugeskr Laeger 1993; 155: 2711–3
   PubMedGoogle Scholar
• Gamier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud A E, Efthymiou M L. Acute Zolpidem poisoning - analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32: 391–404
   PubMedGoogle Scholar
• Wyss P A, Radovanovic D, Meierabt P J. Acute overdose of Zolpidem (Stilnox) (in German). Schweiz Med Wochenschr 1996; 126: 750–6
   PubMedGoogle Scholar
• Goa K L, Heel R C. Zopiclone, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32: 48–65
   PubMed Web of Science ®Google Scholar
• Doble A, Canton T, Malgouris C, et al. The mechanisms of action of zopiclone. Eur Psychiatry 1995; 10(Suppl 3)117S–28S
   Google Scholar
• Zopiclone. Therapeutic Drugs, C Dollery. Churchill Livingstone, Edinburgh 1991; Vol. 2.: Z6–9
   Google Scholar
• O'Hanlon J F. Zopiclone's residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review. Eur Psychiatry 1995; 10(Suppl 3)137S–43S
   Google Scholar
• Allain H, Patat A, Lieury A, et al. Comparative study of the effects of zopiclone (7.5 mg), Zolpidem, flunitrazepam and placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 1995; 10(Suppl 3)129S–35S
   PubMedGoogle Scholar
• Yanagita T. Dependence potential of zopiclone studied in monkeys. Pharmacology 1983; 27(Suppl 2)216–27
   PubMedGoogle Scholar
• Dorian P, Sellers E MH, Caplan H, Hamilton C. Evaluation of zopiclone physical dependency liability in normal volunteers. Pharmacology 1983; 27(Suppl 2)228–34
   PubMedGoogle Scholar
• Aranko K, Henriksson M, Hublin C, Seppalainen A M. Misuse of zopiclone and convulsions during withdrawal. Pharmacopsychiatry 1991; 24: 138–40
   PubMed Web of Science ®Google Scholar
• Fava G A. Amnestic syndrome induced by zopiclone. Eur J Clin Pharmacol 1996; 50: 509
   PubMedGoogle Scholar
• Olkkola K T, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298–305
   PubMed Web of Science ®Google Scholar
• Pichard L, Gillet G, Bonfils C, Domerque J, Thenot J P, Maurel P. Oxidative metabolism of Zolpidem by human liver cytochrome P450. Drug Metab Dispos Biol Fate Chem 1995; 23: 1253–62
   PubMed Web of Science ®Google Scholar
• Jonas J M, Coleman B S, Sheridan A Q, Kalinske R W. Comparative clinical profiles of triazolam versus other shorter-acting hypnotics. J Clin Psychopharmacol 1992; 53(Suppl)19–31
   Google Scholar
• Haefely W, Martin J R, Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990; 11: 452–6
   PubMed Web of Science ®Google Scholar
• Costa E, Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 1996; 17: 192–200
   PubMed Web of Science ®Google Scholar
• Potokar J, Nutt D J. Anxiolytic potential receptor partial agonist. CNS Drugs 1994; 1: 305–15
   Google Scholar
• Van Stevenick A L, Gieschke R, Schoemaker R C, et al. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol. Br J Clin Pharmacol 1996; 41: 565–73
   PubMedGoogle Scholar
• Delinistula A, Berdahtorjman D. Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia - a study report. J Psychiatr Res 1996; 30: 230–50
   Google Scholar
• Thomas S R, Lewis M E, Iversen S D. Correlation of [3H]diazepam binding density with anxiolytic locus in the amygdaloid complex of the rat. Brain Res 1985; 342: 85–90
   PubMedGoogle Scholar
• Fritschy J -M, Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol 1995; 359: 154–94
   PubMed Web of Science ®Google Scholar
• Korpi E R, Seeburg P H, Liiddens H. Modulation of GABAAreceptor tert-[35S]butylbicyclophoshorothionate binding by antagonists: relationship to patterns of subunit expression. J Neurochem 1996; 66: 2179–87
   PubMedGoogle Scholar
• Quirk K, Blurton R, Fletcher S, et al. [3H]L-655, 708, a novel ligand selective for the benzodiazepine site of GABAAreceptors which contain the a5 subunit. Neuropharmacology 1996; 35: 1331–5
   PubMed Web of Science ®Google Scholar
• Doble A, Martin I L. Multiple benzodiazepine receptors: no reason for anxiety. Trends Pharmacol Sci 1992; 13: 76–81
   PubMed Web of Science ®Google Scholar
• Davies P A, Hanna M C, Hales T G, Kirkness E F. Insensi-tivity to anaesthetic agents conferred by a class of GABAAreceptor subunit. Nature 1997; 385: 820–3
   PubMed Web of Science ®Google Scholar
• Tang A H, Smith M W, Carter D B, Im W B, VonVoigtlander P F. U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. J Pharmacol Exp Ther 1995; 275: 761–7
   PubMed Web of Science ®Google Scholar
• Korpi E R, Kuner T, Seeburg P H, Liiddens H. Selective antagonist for the cerebellar granule cell-specific y-amino-butyric acid type A receptor. Mol Pharmacol 1995; 47: 283–9
   PubMedGoogle Scholar